First phase I clinical trial of an HIV-1 subtype D gp140 envelope protein vaccine: immune activity induced in all study participants

被引：9
|
作者：
Huritz, Julia L. [1 ,2 ,4 ]
Lockey, Timothy D. [1 ,3 ]
Jones, Bart [1 ,2 ]
Freiden, Pamela [2 ]
Sealy, Robert [1 ,2 ]
Coleman, John [3 ]
Howlett, Nanna [2 ]
Branum, Kristen [2 ]
Slobod, Karen S. [2 ,5 ]
机构：
[1] St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA
[2] St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN USA
[3] St Jude Childrens Res Hosp, Dept Therapeut Prod & Quality, Memphis, TN USA
[4] Univ Tennessee, Dept Pathol, Knoxville, TN 37996 USA
[5] Univ Tennessee, Hlth Sci Ctr, Dept Pediat, Knoxville, TN 37996 USA
来源：
AIDS | 2008年 / 22卷 / 01期
关键词：
D O I：
10.1097/QAD.0b013e3282f174ed
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
To combat HIV-1 diversity, we are developing a multienvelope vaccine (comprising DNA, vaccinia virus and protein vectors). Toward this goal, we conducted a phase I clinical trial of EnvPro, a gp140 protein formulated in alum. The vaccine was well tolerated and elicited an immune response in every trial participant.
引用
收藏
页码：149 / 151
页数：3
相关论文
共 50 条
  • [21] A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes
    Joseph, Sarah
    Quinn, Killian
    Greenwood, Aldona
    Cope, Alethea V.
    McKay, Paul F.
    Hayes, Peter J.
    Kopycinski, Jakub T.
    Gilmour, Jill
    Miller, Aleisha N.
    Geldmacher, Christof
    Nadai, Yuka
    Ahmed, Mohamed I. M.
    Montefiori, David C.
    Dally, Len
    Bouliotis, George
    Lewis, David J. M.
    Tatoud, Roger
    Wagner, Ralf
    Esteban, Mariano
    Shattock, Robin J.
    McCormack, Sheena
    Weber, Jonathan
    FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [22] Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens
    Center, Rob J.
    Wheatley, Adam K.
    Campbell, Shahan M.
    Gaeguta, Adriana J.
    Peut, Viv
    Alcantara, Sheilajen
    Siebentritt, Carly
    Kent, Stephen J.
    Purcell, Damian F. J.
    VACCINE, 2009, 27 (47) : 6605 - 6612
  • [23] Formulation of HIV-1 clade c envelope protein gp140 into directly compressed solid dosage forms as a potential delivery system for vaginal mucosal vaccination
    Morrow, R.
    Malcolm, K.
    Woolfson, D.
    Donnelly, L.
    Curran, R.
    Shattock, R.
    Andrews, R.
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2009, 61 : A116 - A116
  • [24] Antigenicity and immunogenicity of a novel, acute HIV-1 Tanzanian subtype C gp145 envelope protein for clinical development
    V Polonis
    L Wieczorek
    V Kalyanaraman
    G Matyas
    S Whitney
    C Williams
    S Tovanabutra
    E Sanders-Buell
    M Wesberry
    C Ochsenbauer
    A Chenine
    M Rao
    T Tong
    C Alving
    H Cheng
    S Zolla-Pazner
    N Michael
    T VanCott
    M Marovich
    Retrovirology, 9
  • [25] Antigenicity and immunogenicity of a novel, acute HIV-1 Tanzanian subtype C gp145 envelope protein for clinical development
    Polonis, V.
    Wieczorek, L.
    Kalyanaraman, V.
    Matyas, G.
    Whitney, S.
    Williams, C.
    Tovanabutra, S.
    Sanders-Buell, E.
    Wesberry, M.
    Ochsenbauer, C.
    Chenine, A.
    Rao, M.
    Tong, T.
    Alving, C.
    Cheng, H.
    Zolla-Pazner, S.
    Michael, N.
    VanCott, T.
    Marovich, M.
    RETROVIROLOGY, 2012, 9
  • [26] ASCENT: Phase 2a, randomized, double-blind, placebo controlled study evaluating safety and immunogenicity of two HIV-1 prophylactic vaccine regimens comprising Ad26. Mos4. HIV and either clade C gp140 or bivalent gp140
    Stieh, D. J.
    Tomaka, F.
    Comeaux, C. A.
    Nijs, S.
    Callewaert, K.
    Hendriks, J.
    Euler, Z.
    Tomaras, G. D.
    Alter, G.
    Kublin, J.
    Corey, L.
    McElrath, J.
    Swann, E.
    Robb, M.
    Michael, N.
    Marovich, M.
    Pau, M. G.
    Barouch, D. H.
    Schuitemaker, H.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 98 - 98
  • [27] A Recombinant Vesicular Stomatitis Virus (rVSV) HIV-1 Gag Vaccine Is Safe and Immunogenic in Healthy, HIV-1 Uninfected Phase I Trial Participants
    Fuchs, J. D.
    Frank, I.
    Elizaga, M.
    Kochar, N.
    Allen, M.
    Frahm, N.
    Carter, D. K.
    Li, S.
    Edupuganti, S.
    Kalams, S.
    Sheets, R.
    Pensiero, M.
    Latham, T.
    Egan, M.
    Clarke, D.
    Eldridge, J.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2013, 29 (11) : A74 - A75
  • [28] Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study
    Cosgrove, Catherine A.
    Lacey, Charles J.
    Cope, Alethea V.
    Bartolf, Angela
    Morris, Georgina
    Yan, Celine
    Baden, Susan
    Cole, Tom
    Carter, Darrick
    Brodnicki, Elizabeth
    Shen, Xiaoying
    Joseph, Sarah
    DeRosa, Stephen C.
    Peng, Lili
    Yu, Xuesong
    Ferrari, Guido
    Seaman, Mike
    Montefiori, David C.
    Frahm, Nicole
    Tomaras, Georgia D.
    Stoehr, Wolfgang
    McCormack, Sheena
    Shattock, Robin J.
    PLOS ONE, 2016, 11 (05):
  • [29] Analysis of the Disulfide Bond Arrangement of the HIV-1 Envelope Protein CON-S gp140 ΔCFI Shows Variability in the V1 and V2 Regions
    Go, Eden P.
    Zhang, Ying
    Menon, Sushma
    Desaire, Heather
    JOURNAL OF PROTEOME RESEARCH, 2011, 10 (02) : 578 - 591
  • [30] A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trial
    Hertz, T.
    Logan, M. G.
    Rolland, M.
    Magaret, C. A.
    Rademeyer, C.
    Fiore-Gartland, A.
    Edlefsen, P. T.
    DeCamp, A.
    Ahmed, H.
    Ngandu, N.
    Larsen, B. B.
    Frahm, N.
    Marais, J.
    Thebus, R.
    Geraghty, D.
    Hural, J.
    Corey, L.
    Kublin, J.
    Gray, G.
    McElrath, M. J.
    Mullins, J. I.
    Gilbert, P. B.
    Williamson, C.
    VACCINE, 2016, 34 (47) : 5792 - 5801
12345